14 Analysts Have This To Say About Humana
Portfolio Pulse from Benzinga Insights
Analysts have mixed ratings for Humana (NYSE:HUM) over the past three months, with a recent decrease in the average 12-month price target. The current average target is $363.36, down 9.65% from the previous $402.18. Analysts have adjusted their ratings and price targets based on evolving market conditions and company performance.
May 20, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have mixed ratings for Humana, with a recent decrease in the average 12-month price target to $363.36, down 9.65% from the previous $402.18. This reflects a cautious outlook on the stock.
The mixed ratings and the decrease in the average price target suggest a cautious outlook from analysts. While some analysts have raised their targets, the overall trend is a reduction, indicating potential concerns about future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100